血清抵抗素与社区获得性肺炎患者预后之间的关联

Correlation between serum resistin and prognosis in patients with community-acquired pneumonia

目的探讨社区获得性肺炎(CAP)患者血清抵抗素(Resistin)与其预后之间的关联,分析血清Resistin升高的可能危险因素。方法收集2020年5月至2021年5月期间安徽医科大学第二附属医院确诊的117例CAP患者临床资料和血清样本,ELISA方法检测血清Resistin和炎症因子的水平。结果随着血清Resistin水平的升高,CAP患者住院时间显著延长。本研究中有12例CAP患者死亡,死亡患者血清Resistin水平显著高于存活组。Logistic回归分析发现入院时CAP患者血清Resistin升高增加了住院时间延长、降低了存活率。Spearman关联性分析发现Resistin水平与炎症因子呈显著正相关。进一步回归分析发现,年龄、合并肝脏疾病和脑部疾病均是CAP患者血清Resistin升高的独立危险因素。结论血清Resistin水平与CAP患者不良预后呈显著正相关,合并肝脏疾病和脑部疾病的CAP老年患者血清Resistin更易升高。血清Resistin可能作为预测CAP患者预后的一个早期分子标志物。

Objective To explore the correlation between serum resistin and prognosis in patients with community-acquired pneumonia(CAP)and the potential risk factors of resistin elevation.Methods 117 CAP patients were enrolled from May 2020 to May 2021 in the Department of Respiratory and Critical Care Medicine of the Second Affiliated Hospital of Anhui Medical University.Demographic characteristics and clinical information were extracted.Serum samples were collected.Resistin and inflammatory cytokines were measured by ELISA.Results With the increase of serum resistin level,CAP patients had a significantly longer hospital stay.12 patients with CAP died in this study,and their serum resistin was higher than that in the survival group.Moreover,logistic regression analysis found that serum resistin elevation on admission elevated the hospital stays and down-regulated the survival rate in CAP patients.Additionally,Spearman correlation analysis found that resistin was positively associated with inflammatory cytokines.Further regression analysis found that age,comorbidity with liver disease and brain disease were independent risk factors of resistin elevation in CAP patients.Conclusion Serum resistin on admission is positively correlated with adverse prognosis in CAP patients.It is more prone to elevating in older patients accompanied with liver disease and brain disease.Consequently,resistin can be used as a molecular marker for early diagnosis of prognosis in patients with CAP.